Latent Labs is a frontier AI laboratory building generative models that capture the fundamentals of biology to make it programmable. Founded by Simon Kohl, who previously co-developed AlphaFold 2 and co-led DeepMind's protein design team, Latent Labs empowers drug discovery partners with breakthrough AI technology for unprecedented control over molecular biology.

The company's flagship models, Latent-X1 and Latent-X2, represent frontier AI for protein binder and antibody design. Latent-X2 generates high-affinity antibodies (VHH, scFv) and macrocyclic peptides with drug-like developability profiles and demonstrated low immunogenicity properties that emerge directly from the model without optimization. By jointly modeling all-atom sequences and structures of bound complexes, Latent Labs enables precise epitope targeting and framework control while testing only 4-24 designs per target versus millions in conventional screening.

Backed by Radical Ventures and Sofinnova Partners, with angel investors including Google Chief Scientist Jeff Dean and Anthropic CEO Dario Amodei, Latent Labs is advancing a paradigm shift: designing molecules that work from first principles, transforming the logic of modern drug discovery.